Cannabis Rescheduling: Business Boom and Medical Research Benefits

Rescheduling of Cannabis

• ⚡ President Trump's executive order will fast-track the rescheduling of marijuana from Schedule I to a category similar to steroids and prescription pain medication.
• 💡 This reclassification aims to facilitate medical research into cannabis, allowing for studies on its benefits and potential dangers.
• 🎯 The order is expected to help the 1 in 4 American adults who suffer from chronic pain, with six out of ten using medical marijuana for pain management.

Business and Economic Impact

• 💰 Business leaders, like Jim Hagedorn of Hawthorne Gardening Company, believe the rescheduling will boost the cannabis industry, potentially creating more jobs in America.
• 📉 Hawthorne Gardening Company, which sells supplies to cannabis growers, faced challenges due to marijuana's Schedule I classification, with many other companies going out of business.
• 📈 The federal government has been a significant profiteer in the cannabis space through taxes.

Public Opinion and State Laws

• 📊 Approximately 15% of Americans currently smoke marijuana, more than double the rate from a decade ago.
• 👍 A significant 64% of Americans support the federal legalization of marijuana, though this executive order does not achieve full legalization.
• 📜 Currently, 40 US states permit medical marijuana, and 24 states allow it recreationally.

Opposition and Concerns

• ⚠️ Not all states are in favor of the rescheduling; the Attorney General of Nebraska, along with seven other red state attorneys general, have criticized the move, citing harm in their communities.
• ⚖️ The reclassification places marijuana in the same category as steroids, a significant shift from its previous classification alongside drugs like heroin.